Direct costs in adults with community-acquired pneumonia in emergency clinical hospital
Abstract number: O132
Ratchina S., Shal E., Ustuzhanin I., Asafjeva O., Vandenzhan Y.
Objectives: Community-acquired pneumonia (CAP) is a widespread disease associated with a large economic burden, mostly due to inpatient treatment. Identification of determinants of health care costs could help define strategies for efficient use of existing resources. This study was conducted to identify the direct hospitalisation costs of treating adult patients with CAP in an emergency clinical hospital of RF.
Methods: A prospective observational study was performed in patients admitted to a hospital ward between July 2006 and December 2007 with confirmed diagnosis of CAP. Direct medical costs (year 2007 values, calculated in Russian rubles and converted to Euros) of infection-related hospital resources, including hotel cost, laboratory tests, diagnostic procedures, treatment (antibacterial therapy, adjunctive medical treatment and nondrug therapy) were analyzed.
Results: A total of 127 patients aged from 16 to 87 years (mean age 51.3±17.7 years), 91/127 (71.7%) males, were enrolled. Complications were diagnosed in 88/127 (69%) and concomitant diseases in 105/127 (83%) of patients; 46/127 (36.2%) received antibacterial treatment before admission. Severe CAP was diagnosed in 26/127 (20.5%) of cases; in total 3/127 patients died. Mean ±SD length of hospital stay was 13.4 ± 4.1 days. The median (interquartile range) total hospital cost was [euro]273 ([euro]224317); the distribution of each component was as follows: hotel cost [euro]107 ([euro]92122); laboratory tests [euro]40 ([euro]3452), diagnostic procedures [euro]36 ([euro]2350), antibacterial therapy [euro]56 ([euro]3290), non-antibacterial medical treatment [euro]11 ([euro]620), non-drug therapy [euro]2 ([euro]06).
Conclusion: Major determinants of direct costs in hospitalised adults with CAP were hotel cost due to prolonged hospital stay and antibacterial therapy. They should be considered as key components for further analysis and intervention programs.
|Session name:||19th European Congress of Clinical Microbiology and Infectious Diseases|
|Location:||Helsinki, Finland, 16 - 19 May 2009|
|Back to top|